Search Results
Nov 14, 2025, 09:00 ET Silicon Motion Announces SM8388, the Industry's Leading Power-Efficient PCIe Gen5 8-Channel Enterprise SSD Controller, Delivering 14.4GB/s Performance at Under 5W Power for Nearline SSDs
high-density Nearline deployments. The SM8388 also incorporates enterprise-grade security features, including attestation, secure boot, key wrapping, AES-256 encryption, TCG Opel and a hardware root of trust, ensuring data integrity and protection across AI and cloud storage environments.
More news about: Silicon Motion Technology Corporation
Nov 13, 2025, 16:15 ET Bruin Biometrics Accelerates Pressure Injury Prevention with Artificial Intelligence and Sustainable Innovation
Bruin Biometrics confirmed that its PIPPA™ has achieved both HITRUST and SOC 2 certifications. These certifications build on AES-256 encryption and FIPS 140-2 standards already embedded in the Provizio SEM Scanner, extending end-to-end data protection across the company's digital
More news about: Bruin Biometrics, LLC
Nov 13, 2025, 11:54 ET Introducing Ironclad's Next Wave of AI Agents: Every Agreement is Now an Asset
active assets for the business enabling them to take meaningful action at exactly the right moment." As AES accelerates its use of AI across its businesses, the Legal team leverages Ironclad's Jurist to support that journey
More news about: Ironclad Inc.
Nov 12, 2025, 15:00 ET Princess Cruises' Newest Star Princess to "Sail" Down Colorado Boulevard in America's New Year Celebration® at The Rose Parade® on January 1, 2026
Entertainment Services (AES) is a premier entertainment scenic fabrication company with over 35 years of experience in creating custom-designed and innovative themed environments for live entertainment and theme parks. Renowned for its exceptional craftsmanship and creativity, AES brings visions to life,
More news about: Princess Cruises
Nov 12, 2025, 09:00 ET AES Cleanroom Technology Expands Southeast Footprint with New Office in Research Triangle Park
About AES Cleanroom TechnologyAES Cleanroom Technology is an award-winning leader in modular cleanroom design, manufacturing, and construction for life sciences, pharmaceutical, biotechnology, and advanced manufacturing industries. As a Made-in-USA manufacturer, AES delivers comprehensive,
More news about: AES Cleanroom Technology
Nov 12, 2025, 08:30 ET Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Patients taking medications that can prolong bleeding may experience increased bruising or bleeding at treatment sites. Patients may experience late onset AEs with use of injectable gel implants, including SKINVIVE by JUVÉDERM® ADVERSE EVENTS: The most commonly
More news about: AbbVie
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
and the maximum tolerated dose (MTD) was not reached. There were no Grade 4 adverse events (AEs), no treatment-related deaths, and no serious adverse events (SAEs) occurring in more than one patient. The Grade 3 AEs observed in more than one patient included anemia, decreased neutrophil count, decreased
More news about: iLeukon Therapeutics
Nov 10, 2025, 16:47 ET Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American Society of Nephrology Kidney Week
interest (AESIs); secondary endpoints included the change in UPCR and eGFR from baseline. The primary safety endpoints were met with AEs occurring at similar frequencies in both treatment groups, and no AESIs were reported. One SAE was reported for a patient in the setanaxib group that
More news about: Calliditas Therapeutics
Nov 10, 2025, 09:20 ET AtkinsRéalis Acquires U.S.-based C2AE Architecture and Engineering Firm
built on trust," said Steve Morriss, President, U.S., Latin America, and Minerals & Metals of AtkinsRéalis. "We have seen firsthand the strength of C2AE's team and the alignment of our values through past collaborations. This acquisition is rooted in mutual respect, a shared people-first culture, and
More news about: AtkinsRéalis
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
the 4 mg/kg and 5 mg/kg groups. Grade ≥3 treatment-related AEs (TRAEs) occurred in 59 patients (51.8%) and 34 patients (77.3%) in the 4 mg/kg and 5 mg/kg groups respectively; Treatment-related AEs that led to treatment discontinuation was 2 and 1 patient in each group, respectively.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrated favorable safety and tolerability over 6 months. No severe adverse events (AEs) or serious adverse events (SAEs) were observed, and no hypotension events occurred. All adverse events reported were mild to moderate in severity and
More news about: Innovent Biologics
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
status A safety profile consistent with the selective T cell activation mechanism of action, treatment-related adverse events (AEs) were transient and manageable with supportive care Mechanistic activity validated in paired biopsies and blood samples, with
More news about: Marengo Therapeutics
Nov 07, 2025, 08:00 ET Next-Generation Ultra-Wideband to Power 1.4 Billion Devices by 2030 as Ecosystem Matures and Applications Diversify
Car Connectivity Industry Ecosystem Alliance (ICCE), the Intelligent Car Connectivity Open Alliance (ICCOA), omlox, and the Audio Engineering Society (AES). In the longer term, collaboration between these organizations will benefit a wide range of solution providers, including CEVA, Qorvo, Qualcomm, NXP,
More news about: ABI Research
Nov 07, 2025, 07:00 ET Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
carbonate in reducing serum phosphate levels was demonstrated. Overall, AP301 was safe and well-tolerated. The most common AEs were discolored feces and diarrhea. Diarrhea generally occurred early and resolved without treatment changes. No evidence
More news about: Alebund Pharmaceuticals
Nov 07, 2025, 01:19 ET 雅特力於首爾舉辦2025 AT32 MCU培訓 強化全球開發生態鏈 推動AIoT與邊緣智能應用創新
真亂數產生器：基於物理雜訊源設計，符合NIST SP800-90B標準，提供安全且穩定的金鑰與初始向量（IV）來源，強化資料保護能力。 AES 硬體加解密模組：支援128/192/256-bit金鑰長度與多種加密模式，可搭配DMA與中斷控制，提升資料加解密效能與系統安全性。 CAN-FD
More news about: 雅特力科技股份有限公司
Nov 06, 2025, 08:44 ET EnGenius Releases Broadband Outdoor EOC620 Mobile CPE for Transportation and Remote Operations
support SkyPoint NMS and SkyConnect mobile app for centralized management and easy on-site deployment AES-256 encryption for secure data transmission "With the EOC620, we're bringing the
More news about: EnGenius Technologies, Inc.
Nov 06, 2025, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
tolerability. Two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting to be held December 5-9 in Atlanta, Georgia.Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive
More news about: Lipocine Inc.
Nov 06, 2025, 07:30 ET FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA® 42mg in patients who completed Study 501 or 502. The primary endpoint was safety and tolerability of CAPLYTA®, measured by adverse events (AEs), extrapyramidal symptoms (EPS), suicidality, and changes in laboratory parameters, vital signs, and electrocardiogram (ECG) measures. The secondary
More news about: Johnson & Johnson
Nov 04, 2025, 20:06 ET FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
slowing of SCA disease progression by 50-70% in troriluzole-treated patients compared to matched untreated external controls; > 50% risk reduction in AEs of falls in troriluzole-treated subjects compared to placebo from the safety analysis of the 1-year, double-blind, placebo controlled Study -206; and
More news about: Biohaven Ltd.
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
gastrointestinal (GI) adverse events (AEs), despite two discontinuations due to principal investigator's decisions, and one discontinuation due to subject withdrawal. Safety: No serious adverse events (SAEs) or Grade ≥ 3 AEs, including GI events, were observed.
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 16:13 ET AES Reports Third Quarter 2025 Results
in the Renewables SBU, and an increase in rider revenues due to revised rates at AES Indiana and AES Ohio in the Utilities SBU. This was partially offset by the sale of AES Brasil and the impact of the sell-down of AES Ohio. Third quarter 2025 Adjusted EBITDA with Tax Attributes4,5 (a
More news about: The AES Corporation
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
receive four once-weekly subcutaneous doses of DA-1726 or placebo. The primary objective was to assess safety and tolerability based on adverse events (AEs), serious adverse events (SAEs), treatment-emergent events (TAEs), and discontinuations. Secondary endpoints evaluated PK parameters, including serum
More news about: MetaVia Inc.
Nov 03, 2025, 12:00 ET TotalEnergies EP Ratawi Hub Wins ISA100 Wireless Excellence in Automation Award
designed for monitoring and safety-critical applications. Devices that are certified in conjunction with ISA100's 128-bit Advanced Encryption Standard (AES) enable a robust integration of speed, reliability and cyber resilience to protect personnel, equipment and the environment. For
More news about: The International Society of Automation
Oct 31, 2025, 04:00 ET Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
VES001 had a favourable safety and tolerability profile during the three-month daily dosing regimen, with few adverse events (AEs) reported Results support progressing VES001 into Phase IIb/III trials in people with FTD-GRN, the variant of FTD caused by
More news about: Vesper Bio
Oct 27, 2025, 07:30 ET BTQ and ICTK Sign USD 15M Quantum-Secure Chip Development and Joint Investment Agreement to Advance Global Quantum-Safe Hardware
layer to enable crypto-agile upgrades without changing customer workflows. Early targets include up to 5× Advanced Encryption Standard (AES) throughput versus leading secure hardware, ~1 million digital signatures per second, and <1 microjoule per operation— defense and critical Infrastructure,
More news about: BTQ Technologies Corp.